Organovo Holdings (Seite 104)
eröffnet am 23.10.12 18:24:31 von
neuester Beitrag 11.05.22 09:20:03 von
neuester Beitrag 11.05.22 09:20:03 von
Beiträge: 1.673
ID: 1.177.413
ID: 1.177.413
Aufrufe heute: 0
Gesamt: 314.210
Gesamt: 314.210
Aktive User: 0
ISIN: US68620A2033 · WKN: A2QA6Q · Symbol: 4OR1
0,8840
EUR
+3,27 %
+0,0280 EUR
Letzter Kurs 08.05.24 Tradegate
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,4000 | +49,07 | |
| 4,0600 | +27,67 | |
| 1,6400 | +25,19 | |
| 26,45 | +23,02 | |
| 1,6500 | +22,22 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,5000 | -28,30 | |
| 0,6864 | -32,57 | |
| 2,1300 | -34,41 | |
| 2,5320 | -34,44 | |
| 3,1600 | -38,64 |
Beitrag zu dieser Diskussion schreiben
Feedback
jetzt wollte ich gerade von QSolar in Organovo umschichten, da kackt mir das Teil da drüben um 30% weg. Ich könnte mich gerade in den A.... beißen.
Jetzt hab ich nichts frei und muss den Mist bei QSolar aussitzen. Schade.
Jetzt hab ich nichts frei und muss den Mist bei QSolar aussitzen. Schade.
Antwort auf Beitrag Nr.: 48.359.596 von PhaseDrei am 19.11.14 13:45:51Hallo,
damit sind natürlich 3D-Bioprinter -Brustkrebszellen gemeint zur individuellen Austestung
Als Produktname könnte Ich mir folgendes vorstellen
Exvive3D breast cancer neotissues
Übrigens:
Ein sehr weites Feld, dass bei den Pharmafirmen mit entsprechenden Molekülen in ihrer Onko-Pipeline sicher auf großes
Interesse stoßen dürfte
Gruß, Phase
damit sind natürlich 3D-Bioprinter -Brustkrebszellen gemeint zur individuellen Austestung
Als Produktname könnte Ich mir folgendes vorstellen
Exvive3D breast cancer neotissues
Übrigens:
Ein sehr weites Feld, dass bei den Pharmafirmen mit entsprechenden Molekülen in ihrer Onko-Pipeline sicher auf großes
Interesse stoßen dürfte
Gruß, Phase
Antwort auf Beitrag Nr.: 48.355.828 von PhaseDrei am 19.11.14 07:58:29Hallo,
Hier ein aktueller Vortrag anlässlich des Stem Cell Meeting on the Mesa
im Oktober
http://m.youtube.com/watch?v=bGZMOFpPG6U
Brustkrebs-Test wird das nächste Produkt sein;
Der Vortrag gibt einen wirklich interessanten Überblick
Gruß, Phase
Hier ein aktueller Vortrag anlässlich des Stem Cell Meeting on the Mesa
im Oktober
http://m.youtube.com/watch?v=bGZMOFpPG6U
Brustkrebs-Test wird das nächste Produkt sein;
Der Vortrag gibt einen wirklich interessanten Überblick
Gruß, Phase
Antwort auf Beitrag Nr.: 48.350.629 von PhaseDrei am 18.11.14 16:09:41Hallo
Hier einige Aktuelle Artikel über Organovo:
Das hört sich gut an|
...........
Though too small to be considered an actual organ, the 3D printed exVive3D™ Liver Model has the potential to radically change the field of medicine..."..................
http://3dprintingindustry.com/2014/11/18/organovo-delivers-i…
[urlhttp://3dprint.com/25499/organovo-exvive3d-liver/][/url]
[urlhttp://www.3ders.org/articles/20141118-organovo-announces-commercial-release-of-exvive3d-3d-printed-human-liver-tissue.html][/url]
Gruß, Phase
Hier einige Aktuelle Artikel über Organovo:
Das hört sich gut an|
...........
Though too small to be considered an actual organ, the 3D printed exVive3D™ Liver Model has the potential to radically change the field of medicine..."..................
http://3dprintingindustry.com/2014/11/18/organovo-delivers-i…
[urlhttp://3dprint.com/25499/organovo-exvive3d-liver/][/url]
[urlhttp://www.3ders.org/articles/20141118-organovo-announces-commercial-release-of-exvive3d-3d-printed-human-liver-tissue.html][/url]
Gruß, Phase
Hallo,
in ganzer Länge, weil's so schön ist
Organovo Announces Commercial Release of the exVive3D™ Human Liver Tissue
11/18/2014
SAN DIEGO, Nov. 18, 2014 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today announced the full commercial release of the exVive3DTM Human Liver Tissue for preclinical drug discovery testing. Initially, clients will be able to access the technology through Organovo's contract research services program. This model is intended to provide human-specific data to aid in the prediction of liver tissue toxicity or ADME outcomes in later stage preclinical drug discovery programs.
Organovo's exVive3D Liver Models are bioprinted, living 3D human liver tissues consisting of primary human hepatocytes, stellate, and endothelial cell types, which are found in native human liver. The exVive3D Liver Models are created using Organovo's proprietary 3D bioprinting technology that builds functional living tissues containing precise and reproducible architecture. The tissues are functional and stable for at least 42 days, which enables assessment of drug effects over study durations that well beyond those offered by industry-standard 2D liver cell culture systems.
Organovo has previously shown that exVive3D Liver Models produce important liver proteins including albumin, fibrinogen and transferrin, synthesize cholesterol, and possess inducible cytochrome P450 enzymatic activities, including CYP 1A2 and CYP 3A4. The exVive 3D Liver has successfully differentiated between structurally related compounds with known toxic and non-toxic profiles in human beings, and the model has also been employed successfully in the detection of metabolites at extended time points in vitro. Importantly, the configuration of the bioprinted liver tissues enables both biochemical and histologic data to be collected so that a customer can investigate compound responses at multiple levels.
The durability and functionality of the 3D liver product enable the assessment of the effects of low dose or repeated dosing regimens across a spectrum of biochemical, molecular, and histologic end points. All testing will be performed at Organovo's facility by the Company's laboratory services tissue experts.
For more information or to discuss specific study requirements, clients can contact us at sales@organovo.com, or visit our website at www.organovo.com.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The company plans to market its first product of a planned portfolio offering, a 3D Human Liver Tissue for use in Toxicology and other preclinical drug testing prior to the end of 2014, and remains on track to bring this breakthrough technology to customers. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the market acceptance of the Company's products; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our annual report on Form 10-K filed with the SEC on June 10, 2014 and its report on Form 10-Q filed with the SEC on November 7, 2014, as well as our other filings with the SEC. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.
SOURCE Organovo Holdings, Inc.
Mike Renard, EVP, Commercial Operations, 858-224-1006, mrenard@organovo.com
It's just the beginning!
Gruß, Phase
in ganzer Länge, weil's so schön ist
Organovo Announces Commercial Release of the exVive3D™ Human Liver Tissue
11/18/2014
SAN DIEGO, Nov. 18, 2014 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today announced the full commercial release of the exVive3DTM Human Liver Tissue for preclinical drug discovery testing. Initially, clients will be able to access the technology through Organovo's contract research services program. This model is intended to provide human-specific data to aid in the prediction of liver tissue toxicity or ADME outcomes in later stage preclinical drug discovery programs.
Organovo's exVive3D Liver Models are bioprinted, living 3D human liver tissues consisting of primary human hepatocytes, stellate, and endothelial cell types, which are found in native human liver. The exVive3D Liver Models are created using Organovo's proprietary 3D bioprinting technology that builds functional living tissues containing precise and reproducible architecture. The tissues are functional and stable for at least 42 days, which enables assessment of drug effects over study durations that well beyond those offered by industry-standard 2D liver cell culture systems.
Organovo has previously shown that exVive3D Liver Models produce important liver proteins including albumin, fibrinogen and transferrin, synthesize cholesterol, and possess inducible cytochrome P450 enzymatic activities, including CYP 1A2 and CYP 3A4. The exVive 3D Liver has successfully differentiated between structurally related compounds with known toxic and non-toxic profiles in human beings, and the model has also been employed successfully in the detection of metabolites at extended time points in vitro. Importantly, the configuration of the bioprinted liver tissues enables both biochemical and histologic data to be collected so that a customer can investigate compound responses at multiple levels.
The durability and functionality of the 3D liver product enable the assessment of the effects of low dose or repeated dosing regimens across a spectrum of biochemical, molecular, and histologic end points. All testing will be performed at Organovo's facility by the Company's laboratory services tissue experts.
For more information or to discuss specific study requirements, clients can contact us at sales@organovo.com, or visit our website at www.organovo.com.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The company plans to market its first product of a planned portfolio offering, a 3D Human Liver Tissue for use in Toxicology and other preclinical drug testing prior to the end of 2014, and remains on track to bring this breakthrough technology to customers. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the market acceptance of the Company's products; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our annual report on Form 10-K filed with the SEC on June 10, 2014 and its report on Form 10-Q filed with the SEC on November 7, 2014, as well as our other filings with the SEC. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.
SOURCE Organovo Holdings, Inc.
Mike Renard, EVP, Commercial Operations, 858-224-1006, mrenard@organovo.com
It's just the beginning!
Gruß, Phase
Trading Spotlight
Antwort auf Beitrag Nr.: 48.328.483 von Popeye82 am 15.11.14 10:48:44Hallo,
allen Investierten, denen aufgrund der schwachen Kursperformance der letzten Woche langsam Zweifel kommen, hier noch mal zur stützenden Erinnerung der Chairman' s Letter, der es sicher Wert ist gelesen zu werden.
http://ir.organovo.com/files/doc_downloads/Organovo_Investor…
Gruß, Phase
allen Investierten, denen aufgrund der schwachen Kursperformance der letzten Woche langsam Zweifel kommen, hier noch mal zur stützenden Erinnerung der Chairman' s Letter, der es sicher Wert ist gelesen zu werden.
http://ir.organovo.com/files/doc_downloads/Organovo_Investor…
Gruß, Phase
Antwort auf Beitrag Nr.: 48.328.453 von PhaseDrei am 15.11.14 10:42:55
also könnte hoch oder runter gehen meinst Du?
denke ich auch
also könnte hoch oder runter gehen meinst Du?
denke ich auch
Antwort auf Beitrag Nr.: 48.325.927 von Popeye82 am 14.11.14 20:47:57Hallo,
habe auch nur diesen link;
nach dem für mich unerwarteten, ernüchternden Kursverlauf der letzten 5 Handeltage wird es in der kommenden Woche besonders interessant;
Falls man Boston für Exvive3D nutzen will- was aus meiner Sicht jetzt fraglich erscheint, da ONVOs Session bereits Sonntag stattfindet und man noch keine offizielle News veröffentlicht hat, müssten sie spätestens Montag vor Börsenbeginn News zum Launch veröffentlichen.
Sollte man Boston verstreichen lassen und wir bekommen Mo keine News sehe ich hier durchaus noch weiteres Abwärtspotential;
Die shorties werden nichts unversucht lassen!
so oder so, es könnte Bewegung in den Kurs kommen!
Augen zu und durch! I'm long
Gruß, Phase
habe auch nur diesen link;
nach dem für mich unerwarteten, ernüchternden Kursverlauf der letzten 5 Handeltage wird es in der kommenden Woche besonders interessant;
Falls man Boston für Exvive3D nutzen will- was aus meiner Sicht jetzt fraglich erscheint, da ONVOs Session bereits Sonntag stattfindet und man noch keine offizielle News veröffentlicht hat, müssten sie spätestens Montag vor Börsenbeginn News zum Launch veröffentlichen.
Sollte man Boston verstreichen lassen und wir bekommen Mo keine News sehe ich hier durchaus noch weiteres Abwärtspotential;
Die shorties werden nichts unversucht lassen!
so oder so, es könnte Bewegung in den Kurs kommen!
Augen zu und durch! I'm long
Gruß, Phase
Antwort auf Beitrag Nr.: 48.304.633 von PhaseDrei am 13.11.14 08:20:18
ich bekomme beim, zugeschickten, Link von "RetailInvestorConferences" nur die Präsentationen von AFL, HASI, CMO und NNN auf den Schirm
obwohl er anderes sagt, dass Organovos auch dabei sein muss("Presentations feature the four NYSE companies listed on the right as well as presentations from Organovo Holdings, Sigma Labs, Prospect Street Capital and more")
wisst Ihr das was, oder habt einen Link?
Gruß
P.
ich bekomme beim, zugeschickten, Link von "RetailInvestorConferences" nur die Präsentationen von AFL, HASI, CMO und NNN auf den Schirm
obwohl er anderes sagt, dass Organovos auch dabei sein muss("Presentations feature the four NYSE companies listed on the right as well as presentations from Organovo Holdings, Sigma Labs, Prospect Street Capital and more")
wisst Ihr das was, oder habt einen Link?
Gruß
P.
Antwort auf Beitrag Nr.: 48.287.494 von PhaseDrei am 11.11.14 16:14:17Hallo,
am Montag beginnt die Konferenz in Boston-
Wie ich schon erwähnt habe, rechne ich damit, dass man dieses Event, bei dem zahlreiche Pharmaschwergewichte vertreten sein werden, zur Bekanntgabe der Markteinführung von ExVive3D nutzen wird;
Es verbleiben also noch ganze zwei Handelstage, weshalb ich damit rechne, dass wir weiter moderat steigen und spätestens Freitag wieder die 7 $-Marke nehmen werden.
Entscheidend wird sein, ob man als zusätzliches Bonbon auch erste Kunden und damit indirekt zukünftige Umsätze für ExVive3D bekanntgeben wird;
Nur dann dürfte der Kurs einen richtigen Luftsprung machen und den shorties die Suppe versalzen.
Die Shortquote,weiter hoch, hat in der Periode 15-31.10 sogar noch um 600 K leicht zugelegt.
es ist also noch nicht vorbei!
Settlement Date Short Interest Avg Daily Share Volume Days To Cover
10/31/2014 16,326,488 764,943 21.343405
10/15/2014 15,721,336 1,163,290 13.514546
Read more: http://www.nasdaq.com/symbol/onvo/short-interest#ixzz3Ivhaik…
Gruß, Phase
am Montag beginnt die Konferenz in Boston-
Wie ich schon erwähnt habe, rechne ich damit, dass man dieses Event, bei dem zahlreiche Pharmaschwergewichte vertreten sein werden, zur Bekanntgabe der Markteinführung von ExVive3D nutzen wird;
Es verbleiben also noch ganze zwei Handelstage, weshalb ich damit rechne, dass wir weiter moderat steigen und spätestens Freitag wieder die 7 $-Marke nehmen werden.
Entscheidend wird sein, ob man als zusätzliches Bonbon auch erste Kunden und damit indirekt zukünftige Umsätze für ExVive3D bekanntgeben wird;
Nur dann dürfte der Kurs einen richtigen Luftsprung machen und den shorties die Suppe versalzen.
Die Shortquote,weiter hoch, hat in der Periode 15-31.10 sogar noch um 600 K leicht zugelegt.
es ist also noch nicht vorbei!
Settlement Date Short Interest Avg Daily Share Volume Days To Cover
10/31/2014 16,326,488 764,943 21.343405
10/15/2014 15,721,336 1,163,290 13.514546
Read more: http://www.nasdaq.com/symbol/onvo/short-interest#ixzz3Ivhaik…
Gruß, Phase
Durchsuchen
